Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

(2014) Fariba Navid et al.   JOURNAL OF CLINICAL ONCOLOGY

Successful Multifold Dose Escalation of Anti-GD2Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study

(2011) Brian H. Kushner et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia

(2010) Linda S. Sorkin et al.   PAIN

Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children’s self-reports of pain intensity

(2009) Carl L. von Baeyer et al.   PAIN

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

(2008) Andrew L. Gilman et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY